专肽生物_定制多肽合成服务_多肽合成定制服务_多肽合成厂家_多肽合成公司

iRGD 肿瘤穿透肽修饰的溶瘤腺病毒显示增强的肿瘤转导、肿瘤内传播和抗肿瘤功效。基因疗法。

iRGD (CRGDKGPDC) (Disulfide bridge: C1-C9)是一种由 9 个氨基酸组成的二硫键环肽，由第一位半胱氨酸C与末尾的C巯基之间氧化形成二硫键。它能够与整合素结合后酶解产生 CRGDK ，再与 神经纤毛蛋白-1 (neuropilin-1) 相互作用，从而促进药物的组织渗透，具有靶向肿瘤以及肿瘤渗透的作用。

胃癌是全球最常见的恶性肿瘤之一。5-氟尿嘧啶（5-FU）被确立为局部进展期或转移性胃癌的标准一线化疗药物。然而，肿瘤穿透性差、选择性低及毒副作用等问题严重制约了化疗药物在抗肿瘤治疗中的应用。最新研究表明，新型肿瘤归巢肽iRGD能显著增强化疗药物在多种癌症中的肿瘤穿透能力，而神经纤毛蛋白-1（NRP1）是该过程的关键介导因子。研究通过免疫组化和蛋白质印迹法发现，NRP1蛋白在胃癌组织及细胞系中显著高表达。NRP1过表达与肿瘤分化程度（P=0.021）、肿瘤大小（P=0.004）、临床分期（P=0.028）、淋巴结转移（P=0.032）、TNM分期（P=0.006）及不良预后显著相关。功能实验显示：MTT法、克隆形成实验及Transwell实验证实NRP1能促进胃癌细胞增殖、迁移和侵袭。更重要的是，iRGD可通过NRP1增强5-FU对胃癌细胞的化疗效果。研究提示NRP1可作为胃癌治疗的潜在靶点，iRGD与5-FU联用方案或将为改善胃癌患者预后提供新思路。

iRGD peptide 是一种由 9 个氨基酸组成的环肽，先与 αv-integrins 结合，随后酶解产生 CRGDK/R 与 神经纤毛蛋白-1 (neuropilin-1) 相互作用，从而促进活性分子的组织渗透，具有靶向肿瘤、肿瘤渗透的作用。

iRGD能增强5-氟尿嘧啶对胃癌细胞的体内化疗效果。(A)在5-FU+iRGD治疗组中，HCG27诱导的皮下肿瘤生长速度和重量显著减缓减轻。(B)在5-FU+iRGD治疗组中，NCI-N87诱导的皮下肿瘤生长速度和重量显著减缓减轻。*P < 0.05,**P < 0.01,***P < 0.001。

iRGD通过NRP1增强5-FU对胃癌细胞的化疗效果。(A,C,E,F)MTT实验、集落形成实验和Transwell实验表明，当HCG27细胞的NRP1被沉默时，iRGD无法发挥作用。(B,D,G,H)在NCI-N87-Lenti-NRP1细胞中，5-FU+iRGD显著增强了化疗效果。数据以均值±标准差表示(n=3)。*P<0.05,**P<0.01,***P<0.001。

研究结果表明，神经纤毛蛋白1（NRP1）可能作为胃癌的早期生物标志物和新型治疗靶点。此外，iRGD肽能通过NRP1增强5-氟尿嘧啶（5-FU）对胃癌细胞的治疗效果。

体外研究

iRGD peptide 介导的肿瘤穿透分为三个步骤：与肿瘤脉管系统或肿瘤细胞上的 αv 整合素结合、通过与神经纤毛蛋白-1 (NRP-1) 结合的 C 末端基序的蛋白水解而暴露以及细胞内化。插入 ICOVIR15K 纤维 C 末端的 iRGD peptide 仅在表达 NRP-1 和整合素的 MCF7 细胞中增强结合和内化。iRGD peptide 插入不会损害病毒感染和复制。

iRGD peptide 单独使用对胃癌细胞无明显作用，与 5-FU 联合使用时，iRGD peptide (0.3 μmol/mL) 通过 NRP1 增强 5-FU 对胃癌细胞的化疗疗效。

体内研究

溶瘤腺病毒 ICOVIR15K (ICOVIR15K-iRGD) 中的 iRGD peptide 可增强腺病毒在肿瘤块中的早期传播，并增强小鼠的抗肿瘤效果。

iRGD peptide (4 mmol/kg，静脉注射) 与 5-FU 联合使用可显著抑制携带人胃癌细胞的裸鼠体内的肿瘤生长。

参考文献

Zhang L, et al. Combination of NRP1-mediated iRGD with 5-fluorouracil suppresses proliferation, migration and invasion of gastric cancer cells. Biomed Pharmacother. 2017 Sep;93:1136-1143.  

Peptide H-CRGDKGPDC-NH2 is a Research Peptide with significant interest within the field academic and medical research. Recent citations using H-CRGDKGPDC-NH2 include the following: RGD peptide in cancer targeting: Benefits, challenges, solutions, and possible integrin-RGD interactions H Javid , MA Oryani , N Rezagholinejad- Cancer ..., 2024 - Wiley Online Libraryhttps://onlinelibrary.wiley.com/doi/abs/10.1002/cam4.6800 for enhanced fluorescence visualization of glioblastoma tumors based on HPMA copolymers conjugated with tumor targeting and/or cell-\x90penetrating peptides E Grosmanová, R Pola, M Filipová, M Henry, JL Coll - View, 2024 - Wiley Online Libraryhttps://onlinelibrary.wiley.com/doi/abs/10.1002/VIW.20230116 Anti-PD-1-iRGD Peptide Conjugate Boosts Antitumor Efficacy via Engagement Augmentation and Penetration Enhancement of T cells Y Pan, Q Xue, Y Yang, T Shi, H Wang, X Song, X Yang- bioRxiv, 2023 - biorxiv.orghttps://www.biorxiv.org/content/10.1101/2023.08.04.551949.abstract Isolation of Primary Hepatocytes for Testing Tumor Penetrating Peptides E Savier, P Tuffery, H Bruzzoni-Giovanelli- Cell Penetrating Peptides ..., 2022 - Springerhttps://link.springer.com/protocol/10.1007/978-1-0716-1752-6_26 One-pot synthesis of functional peptide-modified gold nanoparticles for gene delivery X Xu, Y Liu, Y Yang, J Wu, M Cao, L Sun - Colloids and Surfaces A ..., 2022 - Elsevierhttps://www.sciencedirect.com/science/article/pii/S092777572200245X Inhibitory potential of iRGD peptide-conjugated garcinol-loaded biodegradable nanoparticles in rat colorectal carcinoma B Paul, RH Gaonkar , D Dutta , R Dasi , B Mukherjee - Biomaterials ..., 2022 - Elsevierhttps://www.sciencedirect.com/science/article/pii/S0928493122000741 Using peptides to promote delivery and improve anti-tumour efficacy of liposomal drug JG Altin, Y Zhao - Journal of Drug Targeting, 2022 - Taylor & Francishttps://www.tandfonline.com/doi/abs/10.1080/1061186X.2021.2020799 Tumor-\x90homing peptide and its utility for advanced cancer medicine E Kondo , H Iioka , K Saito - Cancer Science, 2021 - Wiley Online Libraryhttps://onlinelibrary.wiley.com/doi/abs/10.1111/cas.14909 Recent progress in functional peptides designed for tumor-targeted imaging and therapy XY Wang , YH Wang, Z Song, XY Hu, JP Wei- Journal of Materials ..., 2021 - pubs.rsc.orghttps://pubs.rsc.org/en/content/articlehtml/2021/tc/d0tc05405d Tumor penetrating peptide-functionalized tenascin-C antibody for glioblastoma targeting P Lingasamy , AH Laarmann- Current cancer drug ..., 2021 - ingentaconnect.comhttps://www.ingentaconnect.com/content/ben/ccdt/2021/00000021/00000001/art00006 68Ga-\x90labeling of internalizing RGD (iRGD) peptide functionalized with DOTAGA and NODAGA chelators D Satpati, K Vats, R Sharma- Journal of Peptide ..., 2020 - Wiley Online Libraryhttps://onlinelibrary.wiley.com/doi/abs/10.1002/psc.3241 Fluorescent RGD-based pro-apoptotic peptide conjugates as mitochondria-targeting probes for enhanced anticancer activities SFA Rizvi , S Mu, Y Wang, S Li, H Zhang - Biomedicine & Pharmacotherapy, 2020 - Elsevierhttps://www.sciencedirect.com/science/article/pii/S0753332220303711 In vivo tumor gene delivery using novel peptideticles: pH-\x90responsive and ligand targeted core-shell nanoassembly M Alipour , A Majidi , F Molaabasi - journal of cancer, 2018 - Wiley Online Libraryhttps://onlinelibrary.wiley.com/doi/abs/10.1002/ijc.31577 Design of an amphiphilic iRGD peptide and self-assembling nanovesicles for improving tumor accumulation and penetration and the photodynamic efficacy of the Y Jiang, X Pang, R Liu, Q Xiao , P Wang- applied materials & ..., 2018 - ACS Publicationshttps://pubs.acs.org/doi/abs/10.1021/acsami.8b11699 Peptide-decorated polymeric nanomedicines for precision cancer therapy H Sun , Y Dong, J Feijen , Z Zhong - Journal of controlled release, 2018 - Elsevierhttps://www.sciencedirect.com/science/article/pii/S0168365918305686 Peptides for tumor-specific drug targeting: State of the art and beyond M Roveri, M Bernasconi , JC Leroux - Journal of Materials ..., 2017 - pubs.rsc.orghttps://pubs.rsc.org/en/content/articlehtml/2017/tb/c7tb00318h Tumor-penetrating peptide fused to a pro-apoptotic peptide facilitates effective gastric cancer therapy Y Huang, X Li, H Sha, L Zhang, X Bian- Oncology ..., 2017 - spandidos-publications.comhttps://www.spandidos-publications.com/10.3892/or.2017.5440 iRGD-targeted delivery of a pro-apoptotic peptide activated by cathepsin B inhibits tumor growth and metastasis in mice W Qifan, N Fen, X Ying, F Xinwei, D Jun, Z Ge - Tumor Biology, 2016 - Springerhttps://link.springer.com/article/10.1007/s13277-016-4961-x iRGD peptide conjugation potentiates intraperitoneal tumor delivery of paclitaxel with polymersomes L Simón-Gracia , H Hunt, P Scodeller , J Gaitzsch - Biomaterials, 2016 - Elsevierhttps://www.sciencedirect.com/science/article/pii/S0142961216303544 Coupling Gd-‘DTPA with a bispecific, recombinant protein anti-‘EGFR-‘iRGD complex improves tumor targeting in MRI X Xin, H Sha, J Shen, B Zhang , B Zhu- Oncology ..., 2016 - spandidos-publications.comhttps://www.spandidos-publications.com/or/35/6/3227 Tumor-penetrating iRGD peptide inhibits metastasis KN Sugahara, GB Braun , TH de Mendoza - Molecular cancer ..., 2015 - AACRhttps://aacrjournals.org/mct/article-abstract/14/1/120/130571 Increasing tumor accessibility with conjugatable disulfide-bridged tumor-penetrating peptides for cancer diagnosis and treatment VR Kotamraju, S Sharma, P Kolhar - Cancer: Basic and ..., 2015 - journals.sagepub.comhttps://journals.sagepub.com/doi/abs/10.4137/BCBCR.S29426 Enhancing accumulation and penetration of HPMA copolymer-doxorubicin conjugates in 2D and 3D prostate cancer cells via iRGD conjugation with an MMP-2 ZH Peng , J Kopecek - Journal of the American Chemical Society, 2015 - ACS Publicationshttps://pubs.acs.org/doi/abs/10.1021/jacs.5b00922 Targeting peptide iRGD-conjugated amphiphilic chitosan-co-PLA/DPPE drug delivery system for enhanced tumor therapy X Nie, J Zhang, Q Xu, X Liu, Y Li, Y Wu- Journal of Materials ..., 2014 - pubs.rsc.orghttps://pubs.rsc.org/en/content/articlehtml/2014/tb/c3tb21744b Amphipathic tail-anchoring peptide is a promising therapeutic agent for prostate cancer treatment G De, JK Ko , T Tan, H Zhu , H Li , J Ma - Oncotarget, 2014 - ncbi.nlm.nih.govhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4202157/ Near-infrared Dye® 800CW-conjugated disulfide-based cyclic RGD peptide c (CRGDKGPDC) and its DOTA analog A Chopra - 2012 - europepmc.orghttps://europepmc.org/books/nbk100265 Synthesis and evaluation of new iRGD peptide analogs for tumor optical imaging Y Ye, L Zhu , Y Ma, G Niu , X Chen - Bioorganic & medicinal chemistry letters, 2011 - Elsevierhttps://www.sciencedirect.com/science/article/pii/S0960894X10018767 Near-infrared Dye® 800CW-conjugated disulfide-based cyclic RGD peptide c (CRGDKGPDC) and its DOTA analog Ac-Cys (IRDye800CW)-iRGD and DOTA-Cys A Chopra - europepmc.orghttps://europepmc.org/books/n/micad/cys800cwirgd/?extid=20641640&src=med

Peptide H-CRGDKGPDC-OH is a Research Peptide with significant interest within the field academic and medical research. Recent citations using H-CRGDKGPDC-OH include the following: RGD peptide in cancer targeting: Benefits, challenges, solutions, and possible integrin-RGD interactions H Javid , MA Oryani , N Rezagholinejad- Cancer ..., 2024 - Wiley Online Libraryhttps://onlinelibrary.wiley.com/doi/abs/10.1002/cam4.6800 for enhanced fluorescence visualization of glioblastoma tumors based on HPMA copolymers conjugated with tumor targeting and/or cell-\x90penetrating peptides E Grosmanová, R Pola, M Filipová, M Henry, JL Coll - View, 2024 - Wiley Online Libraryhttps://onlinelibrary.wiley.com/doi/abs/10.1002/VIW.20230116 Isolation of Primary Hepatocytes for Testing Tumor Penetrating Peptides E Savier, P Tuffery, H Bruzzoni-Giovanelli- Cell Penetrating Peptides ..., 2022 - Springerhttps://link.springer.com/protocol/10.1007/978-1-0716-1752-6_26 One-pot synthesis of functional peptide-modified gold nanoparticles for gene delivery X Xu, Y Liu, Y Yang, J Wu, M Cao, L Sun - Colloids and Surfaces A ..., 2022 - Elsevierhttps://www.sciencedirect.com/science/article/pii/S092777572200245X Inhibitory potential of iRGD peptide-conjugated garcinol-loaded biodegradable nanoparticles in rat colorectal carcinoma B Paul, RH Gaonkar , D Dutta , R Dasi , B Mukherjee - Biomaterials ..., 2022 - Elsevierhttps://www.sciencedirect.com/science/article/pii/S0928493122000741 Using peptides to promote delivery and improve anti-tumour efficacy of liposomal drug JG Altin, Y Zhao - Journal of Drug Targeting, 2022 - Taylor & Francishttps://www.tandfonline.com/doi/abs/10.1080/1061186X.2021.2020799 Recent progress in functional peptides designed for tumor-targeted imaging and therapy XY Wang , YH Wang, Z Song, XY Hu, JP Wei- Journal of Materials ..., 2021 - pubs.rsc.orghttps://pubs.rsc.org/en/content/articlehtml/2021/tc/d0tc05405d Tumor penetrating peptide-functionalized tenascin-C antibody for glioblastoma targeting P Lingasamy , AH Laarmann- Current cancer drug ..., 2021 - ingentaconnect.comhttps://www.ingentaconnect.com/content/ben/ccdt/2021/00000021/00000001/art00006 Nanoparticles modified with vasculature-homing peptides for targeted cancer therapy and angiogenesis imaging E Seyyednia , F Oroojalian , B Baradaran - Journal of controlled ..., 2021 - Elsevierhttps://www.sciencedirect.com/science/article/pii/S0168365921004582 68Ga-\x90labeling of internalizing RGD (iRGD) peptide functionalized with DOTAGA and NODAGA chelators D Satpati, K Vats, R Sharma- Journal of Peptide ..., 2020 - Wiley Online Libraryhttps://onlinelibrary.wiley.com/doi/abs/10.1002/psc.3241 Fluorescent RGD-based pro-apoptotic peptide conjugates as mitochondria-targeting probes for enhanced anticancer activities SFA Rizvi , S Mu, Y Wang, S Li, H Zhang - Biomedicine & Pharmacotherapy, 2020 - Elsevierhttps://www.sciencedirect.com/science/article/pii/S0753332220303711 In vivo tumor gene delivery using novel peptideticles: pH-\x90responsive and ligand targeted core-shell nanoassembly M Alipour , A Majidi , F Molaabasi - journal of cancer, 2018 - Wiley Online Libraryhttps://onlinelibrary.wiley.com/doi/abs/10.1002/ijc.31577 Design of an amphiphilic iRGD peptide and self-assembling nanovesicles for improving tumor accumulation and penetration and the photodynamic efficacy of the Y Jiang, X Pang, R Liu, Q Xiao , P Wang- applied materials & ..., 2018 - ACS Publicationshttps://pubs.acs.org/doi/abs/10.1021/acsami.8b11699 Peptide-decorated polymeric nanomedicines for precision cancer therapy H Sun , Y Dong, J Feijen , Z Zhong - Journal of controlled release, 2018 - Elsevierhttps://www.sciencedirect.com/science/article/pii/S0168365918305686 Peptides for tumor-specific drug targeting: State of the art and beyond M Roveri, M Bernasconi , JC Leroux - Journal of Materials ..., 2017 - pubs.rsc.orghttps://pubs.rsc.org/en/content/articlehtml/2017/tb/c7tb00318h Tumor-penetrating peptide fused to a pro-apoptotic peptide facilitates effective gastric cancer therapy Y Huang, X Li, H Sha, L Zhang, X Bian- Oncology ..., 2017 - spandidos-publications.comhttps://www.spandidos-publications.com/10.3892/or.2017.5440 iRGD-targeted delivery of a pro-apoptotic peptide activated by cathepsin B inhibits tumor growth and metastasis in mice W Qifan, N Fen, X Ying, F Xinwei, D Jun, Z Ge - Tumor Biology, 2016 - Springerhttps://link.springer.com/article/10.1007/s13277-016-4961-x iRGD peptide conjugation potentiates intraperitoneal tumor delivery of paclitaxel with polymersomes L Simón-Gracia , H Hunt, P Scodeller , J Gaitzsch - Biomaterials, 2016 - Elsevierhttps://www.sciencedirect.com/science/article/pii/S0142961216303544 Coupling Gd-‘DTPA with a bispecific, recombinant protein anti-‘EGFR-‘iRGD complex improves tumor targeting in MRI X Xin, H Sha, J Shen, B Zhang , B Zhu- Oncology ..., 2016 - spandidos-publications.comhttps://www.spandidos-publications.com/or/35/6/3227 Tumor-penetrating iRGD peptide inhibits metastasis KN Sugahara, GB Braun , TH de Mendoza - Molecular cancer ..., 2015 - AACRhttps://aacrjournals.org/mct/article-abstract/14/1/120/130571 Increasing tumor accessibility with conjugatable disulfide-bridged tumor-penetrating peptides for cancer diagnosis and treatment VR Kotamraju, S Sharma, P Kolhar - Cancer: Basic and ..., 2015 - journals.sagepub.comhttps://journals.sagepub.com/doi/abs/10.4137/BCBCR.S29426 Enhancing accumulation and penetration of HPMA copolymer-doxorubicin conjugates in 2D and 3D prostate cancer cells via iRGD conjugation with an MMP-2 ZH Peng , J Kopecek - Journal of the American Chemical Society, 2015 - ACS Publicationshttps://pubs.acs.org/doi/abs/10.1021/jacs.5b00922 Targeting peptide iRGD-conjugated amphiphilic chitosan-co-PLA/DPPE drug delivery system for enhanced tumor therapy X Nie, J Zhang, Q Xu, X Liu, Y Li, Y Wu- Journal of Materials ..., 2014 - pubs.rsc.orghttps://pubs.rsc.org/en/content/articlehtml/2014/tb/c3tb21744b Amphipathic tail-anchoring peptide is a promising therapeutic agent for prostate cancer treatment G De, JK Ko , T Tan, H Zhu , H Li , J Ma - Oncotarget, 2014 - ncbi.nlm.nih.govhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4202157/ Near-infrared Dye® 800CW-conjugated disulfide-based cyclic RGD peptide c (CRGDKGPDC) and its DOTA analog A Chopra - 2012 - europepmc.orghttps://europepmc.org/books/nbk100265 Synthesis and evaluation of new iRGD peptide analogs for tumor optical imaging Y Ye, L Zhu , Y Ma, G Niu , X Chen - Bioorganic & medicinal chemistry letters, 2011 - Elsevierhttps://www.sciencedirect.com/science/article/pii/S0960894X10018767 Near-infrared Dye® 800CW-conjugated disulfide-based cyclic RGD peptide c (CRGDKGPDC) and its DOTA analog Ac-Cys (IRDye800CW)-iRGD and DOTA-Cys A Chopra - europepmc.orghttps://europepmc.org/books/n/micad/cys800cwirgd/?extid=20641640&src=med

二硫键广泛存在与蛋白结构中，对稳定蛋白结构具有非常重要的意义，二硫键一般是通过序列中的2个Cys的巯基，经氧化形成。
 

形成二硫键的方法很多：空气氧化法，DMSO氧化法，过氧化氢氧化法等。
 

二硫键的合成过程，  可以通过Ellman检测以及HPLC检测方法对其反应进程进行监测。  
   

如果多肽中只含有1对Cys，那二硫键的形成是简单的。多肽经固相或液相合成，然后在pH8-9的溶液中进行氧化。      
 

当需要形成2对或2对以上的二硫键时，合成过程则相对复杂。尽管二硫键的形成通常是在合成方案的最后阶段完成，但有时引入预先形成的二硫化物是有利于连合或延长肽链的。通常采用的巯基保护基有trt, Acm, Mmt, tBu, Bzl, Mob, Tmob等多种基团。我们分别列出两种以2-Cl树脂和Rink树脂为载体合成的多肽上多对二硫键形成路线：
 

二硫键反应条件选择    
 

 二硫键即为蛋白质或多肽分子中两个不同位点Cys的巯基（-SH）被氧化形成的S-S共价键。 一条肽链上不同位置的氨基酸之间形成的二硫键，可以将肽链折叠成特定的空间结构。多肽分 子通常分子量较大，空间结构复杂，结构中形成二硫键时要求两个半胱氨酸在空间距离上接近。 此外，多肽结构中还原态的巯基化学性质活泼，容易发生其他的副反应，而且肽链上其他侧链 也可能会发生一系列修饰，因此，肽链进行修饰所选取的氧化剂和氧化条件是反应的关键因素， 反应机理也比较复杂，既可能是自由基反应，也可能是离子反应。      

反应条件有多种选择，比如空气氧化，DMSO氧化等温和的氧化过程，也可以采用H2O2，I2， 汞盐等激烈的反应条件。
 

空气氧化法： 空气氧化法形成二硫键是多肽合成中最经典的方法，通常是将巯基处于还原态的多肽溶于水中，在近中性或弱碱性条件下（PH值6.5-10），反应24小时以上。为了降低分子之间二硫键形成的可能，该方法通常需要在低浓度条件下进行。
 

碘氧化法：将多肽溶于25%的甲醇水溶液或30%的醋酸水溶液中，逐滴滴加10-15mol/L的碘进行氧化，反应15-40min。当肽链中含有对碘比较敏感的Tyr、Trp、Met和His的残基时，氧化条件要控制的更精确，氧化完后，立即加入维生素C或硫代硫酸钠除去过量的碘。 当序列中有两对或多对二硫键需要成环时，通常有两种情况：
 

自然随机成环:       序列中的Cys之间随机成环，与一对二硫键成环条件相似；
 

定点成环：       定点成环即序列中的Cys按照设计要求形成二硫键，反应过程相对复杂。在 固相合成多肽之前，需要提前设计几对二硫键形成的顺序和方法路线，选择不同的侧链 巯基保护基，利用其性质差异，分步氧化形成两对或多对二硫键。       通常采用的巯基保护 基有trt, Acm, Mmt, tBu, Bzl, Mob, Tmob等多种基团。

靶向多肽可以根据其功能和用途分为不同的类别。在PDC（多肽偶联药物）中，靶向多肽通常被分为细胞穿透肽和细胞靶向肽两大类。

细胞穿透肽：这类多肽能够跨越细胞膜，转运具有生物活性的大分子物质，如多肽、蛋白质、核酸等化学药物，使其顺利进入细胞。一些常见的细胞穿透肽包括Pep-1、Pentratin、PepFact14、Transportan等。

细胞靶向肽：这类多肽的作用主要是引导化学药物或生物活性分子与特定类型的细胞结合，以提高其靶向性和治疗效率。常见的细胞靶向肽包括PEGA、生长激素抑制素类似物、蛙皮素类似物、RGD肽类等。

RGD肽-说明

RGD肽是指含有由Arg-Gly-Asp三个氨基酸组成的序列多肽，有直线肽和环肽之分。它们是许多细胞外基质蛋白（如VN、FN、FGN、胶原等）等最小识别短肽序列。

研究发现，RGD序列肽具有广泛的生物活性，可用于心血管疾病、骨质疏松和炎症等疾病的治疗，还可以预防和治疗由细胞粘附异常而导致的肿瘤，尤其是发展性肿瘤的转移；另一方面，RGD 序列肽又可作为兴奋剂，促进损伤的器官与组织的再生、伤口的愈合等等，RGD作为某些整合素的受体，其选择性部分依赖于RGD的构象以及RGD周围的氨基酸残基。

为此，近几年，许多科技工作者合成了一系列RGD三肽、四肽、五肽等，还合成了RGD环肽、双线肽、RGD模拟肽等等。为了满足客户对各种RGD序列肽的需求，专肽生物提供最广泛的RGD序列肽库，以满足科研工作者对RGD肽的需求。

专肽生物提供各种RGD肽的现货，缩短科研工作者的项目时间，例如c(RGDfK)、c(RGDfC)、c(RADyK)、c(RGDyK)、c(RADfC)、环状多肽c(RGDfK)-巯基乙酸、c(RGDfK)-PEG2-巯基乙酸、Mpa-Ahx-c(RGDfK)、环状多肽c(RGDfK)-半胱氨酸、DOTA-c(RGDfK)、NOTA-c(RGDfK)、NOTA-c(RGDyK)、DOTA-c(RGDyK)、E[c(RGDfK)]2、E[c(RGDyK)]2、DDDDD-c(RGDfK)等等，具体可咨询销售人员。